{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:44:32Z","timestamp":1782823472048,"version":"3.54.5"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety in routine clinical practice of insulin glargine\/lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) according to age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient\u2010level data were pooled from 1316 adults with T2D inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi for 24\u2009weeks. Participants were classified into age subgroups of younger than 65\u2009years (N\u00a0=\u00a0806) and\u200965\u2009years or older (N\u00a0=\u00a0510).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with participants aged younger than 65\u2009years, those aged 65\u2009years or older had a numerically lower mean body mass index (31.6 vs. 32.6\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), a longer median diabetes duration (11.0 vs. 8.0\u2009years), were more likely to receive prior basal insulin (48.4% vs. 43.5%) and had a lower mean HbA1c (8.93% [74.10\u2009mmol\/mol] vs. 9.22% [77.28\u2009mmol\/mol]). Similar and clinically relevant reductions in HbA1c and fasting plasma glucose from baseline to week 24 of iGlarLixi therapy were observed regardless of age. At 24\u2009weeks, least\u2010squares adjusted mean (95% confidence interval [CI]) change in HbA1c from baseline was \u20131.55% (\u20131.65% to \u20131.44%) in those aged 65\u2009years or older and \u20131.42% (\u20131.50% to \u20131.33%) in those aged younger than 65\u2009years (95% CI: \u20130.26% to 0.00%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.058 between subgroups). Low incidences of gastrointestinal adverse events and hypoglycaemic episodes were reported in both age subgroups. iGlarLixi decreased mean body weight from baseline to week 24 in both subgroups (\u20131.6\u2009kg in those aged \u2265\u200965\u2009years and \u20132.0\u2009kg in those aged &lt;\u200965\u2009years).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iGlarLixi is effective and well tolerated in both younger and older people with uncontrolled T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15027","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T23:28:08Z","timestamp":1677022088000},"page":"1723-1730","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["<scp>iGlarLixi<\/scp>\n                    (insulin glargine 100\u00a0\n                    <scp>U<\/scp>\n                    \/\n                    <scp>ml<\/scp>\n                    plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A\n                    <scp>REALI<\/scp>\n                    pooled analysis of prospective real\u2010world data"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8703-0522","authenticated-orcid":false,"given":"Cristian","family":"Guja","sequence":"first","affiliation":[{"name":"Department of Diabetes, Nutrition and Metabolic Disease Carol Davila University of Medicine and Pharmacy  Bucharest Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos Tibor","family":"Kis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Centrum Szent J\u00e1nos Hospital  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Haluz\u00edk","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Experimental Medicine and Charles University  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Bonnemaire","sequence":"additional","affiliation":[{"name":"General Medicines Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Bigot","sequence":"additional","affiliation":[{"name":"IVIDATA  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Tournay","sequence":"additional","affiliation":[{"name":"International Drug Development Institute (IDDI)  Louvain\u2010la\u2010Neuve Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-5740","authenticated-orcid":false,"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[{"name":"Institute of Clinical Trials and Methodology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7310","authenticated-orcid":false,"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Internal Medicine II Medical Centre \u2013 Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0039-6"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S013"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-122"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010183"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1978974"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2018.11.009"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01128-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-060852"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.2288"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.15027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.15027","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:45:36Z","timestamp":1761878736000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/dom.15027"],"URL":"https:\/\/doi.org\/10.1111\/dom.15027","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15027\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15027\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15027\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15027\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15027\/v1\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"2022-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}